Empowering patients and caregivers with clear, scientifically accurate medical information they can trust is integral to what we do. Andrew Perez-Viñas, a Medical Review Manager at Daiichi Sankyo, shares his commitment to ensuring medical materials are accurate and easy to understand—especially to those with limited health literacy or language barriers.
My decision to devote my career to oncology is deeply personal. During my senior year in college, my father was diagnosed with cholangiocarcinoma, or bile duct cancer. As one of his caregivers…
Not all breast cancers are the same. This is particularly true about metastatic breast cancer versus early-stage breast cancer in terms of how the disease spreads, its prognosis, treatment options, and even the patient journey.
Business development is the craft of making connections. Whether with other companies or within our organization, we need to build those bonds that allow us to be successful.
Cancer research and development is a dynamic and ever-evolving field. One significant area of focus is the role of HER2.
The Galien Foundation has recognized Daiichi Sankyo’s HER2 directed antibody drug conjugate (ADC) with the prestigious 2024 Prix Galien USA Award for Best Biotechnology Product.
A career of building hope for people with cancer began with a single childhood moment for our Vice President, Global Team Leader, Oncology Research & Development, Dalila Sellami, MD.